English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 8 April 2020, 18:00 HKT/SGT

Source: Novotech
Novotech Data Shows Majority of Australian Sites are Open for Clinical Trial Activity
- Part of New Series of COVID-19 Asia-Pacific Bulletins

SYDNEY, Apr 8, 2020 - (ACN Newswire) - Asia-Pacific's largest specialist biotech CRO Novotech said the top 10 biotech sites in Australia were open for clinical trial activity with many sites modifying their practices to ensure continuity of operations.

View and Download the COVID-19 Australia Data Bulletin here. https://novotech-cro.com/covid-19-notice

The data is part of a new series prepared for Novotech clients detailing the current status of trials in the Asia-Pacific during the global COVID-19 crisis.

Novotech CEO Dr John Moller said the Bulletin series taps local knowledge of fundamentals in the sector and shows which countries in the region are able to support clinical research for Novotech and its clients during this time.

"While the situation is always evolving, Australia appears to be managing the crisis well. Our sites have changed how they manage trials in line with Australian Government health guidelines and most are still able to deliver the clinical trial services we need for our clients," said Dr Moller. "Study delays caused by COVID-19 can be rapidly addressed by activating new sites in Australia and Asia."

Australia has attractive start-up times, world leading investigators and research teams, and valuable rebates of up to 43.5% on clinical trial spend.

About Novotech

Novotech, established in 1996, is internationally recognized as the leading full-service contract research organization (CRO) in Asia-Pacific. Novotech provides clinical development services across all clinical trial phases and therapeutic areas and has been instrumental in the success of over a thousand Phase I - IV clinical trials for biotech companies.

Novotech obtained the ISO 27001, the best-known standard in the ISO family, providing the requirements for an Information Security Management System. Together with the ISO 9001 Quality Management system, Novotech aims at the highest IT security and quality standards for patients and biotechnology companies. Visit http://novotech-cro.com.

For RFP enquiries: Please fill out the form available at https://novotech-cro.com/talk-to-an-expert

Media Contact
Susan Fitzpatrick-Napier
[email protected]
AU: +61 2 8218 2144
USA: +1 415 951 3228
Asia: +65 3159 3427

Topic: Clinical Trial Results
Sectors: BioTech, HealthCare
From the Asia Corporate News Network

Copyright © 2020 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.


Novotech Releated News
June 26, 2020 09:00 HKT/SGT
노보텍 (Novotech), 한국의 병상 1,300개 규모 부산대학교병원과 파트너십 체결
June 26, 2020 09:00 HKT/SGT
노보텍 (Novotech) 웨비나: 아시아 태평양 지역이 간학 분야에서 진행 중이거나 예정된 전세계 임상시험의 60%를 유치하는 이유
June 22, 2020 10:00 HKT/SGT
Novotech网络研讨会:亚太地区为什么能够吸引全球 60% 正在进行和计划进行的肝病临床试验
June 22, 2020 10:00 HKT/SGT
Novotech網絡研討會:亞太地區為什麼能夠吸引全球 60% 正在進行和計劃進行的肝病臨床試驗
June 18, 2020 11:00 HKT/SGT
Novotech Partners with South Korea's Pusan National University Hospital
More news >>
Copyright © 2020 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6653 1210 | Tokyo: +81 3 6859 8575